Form 4: Oruka Therapeutics President Sells Shares
Insider Transaction (Form 4)
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 10,000 shares of common stock on November 12, 2026.
Summary
- Option exercise/conversion: acquired 8,542 Common Stock at $12.50 ($106,775) on November 12, 2026; holds 22,761 after (Direct).
- Option exercise/conversion: acquired 1,458 Common Stock at $34.39 ($50,141) on November 12, 2026; holds 24,219 after (Direct).
- Open-market sale: disposed of 500 Common Stock at $101.98 ($50,988) on November 12, 2026; holds 23,719 after (Direct).
- Open-market sale: disposed of 801 Common Stock at $103.16 ($82,628) on November 12, 2026; holds 22,918 after (Direct).
- Open-market sale: disposed of 799 Common Stock at $104.25 ($83,296) on November 12, 2026; holds 22,119 after (Direct).
- Open-market sale: disposed of 6,842 Common Stock at $105.28 ($720,330) on November 12, 2026; holds 15,277 after (Direct).
- Open-market sale: disposed of 958 Common Stock at $106.18 ($101,717) on November 12, 2026; holds 14,319 after (Direct).
- Open-market sale: disposed of 100 Common Stock at $107.00 ($10,700) on November 12, 2026; holds 14,219 after (Direct).
- Option exercise/conversion: disposed of 8,542 Employee Stock Option (right to buy) on November 12, 2026; holds 67,834 after (Direct).
- Option exercise/conversion: disposed of 1,458 Employee Stock Option (right to buy) on November 12, 2026; holds 55,417 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,049,658 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Arjun Agarwal — Officer (Senior Vice President, Finance)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-12 | Option exercise/conversion | Common Stock | 8,542 | $13 | $106.8K | 22,761 |
| 2026-11-12 | Option exercise/conversion | Common Stock | 1,458 | $34 | $50.1K | 24,219 |
| 2026-11-12 | Open-market sale | Common Stock | 500 | $102 | $51.0K | 23,719 |
| 2026-11-12 | Open-market sale | Common Stock | 801 | $103 | $82.6K | 22,918 |
| 2026-11-12 | Open-market sale | Common Stock | 799 | $104 | $83.3K | 22,119 |
| 2026-11-12 | Open-market sale | Common Stock | 6,842 | $105 | $720.3K | 15,277 |
| 2026-11-12 | Open-market sale | Common Stock | 958 | $106 | $101.7K | 14,319 |
| 2026-11-12 | Open-market sale | Common Stock | 100 | $107 | $10.7K | 14,219 |
| 2026-11-12 | Option exercise/conversion | Employee Stock Option (right to buy) | 8,542 | — | — | 67,834 |
| 2026-11-12 | Option exercise/conversion | Employee Stock Option (right to buy) | 1,458 | — | — | 55,417 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-12 | Option exercise/conversion (8,542 shares) |
| 2026-11-12 | Option exercise/conversion (1,458 shares) |
| 2026-11-12 | Open-market sale (500 shares) |
| 2026-11-12 | Open-market sale (801 shares) |
| 2026-11-12 | Open-market sale (799 shares) |
| 2026-11-12 | Open-market sale (6,842 shares) |
| 2026-11-12 | Open-market sale (958 shares) |
| 2026-11-12 | Open-market sale (100 shares) |
| 2026-11-12 | Option exercise/conversion (8,542 shares) |
| 2026-11-12 | Option exercise/conversion (1,458 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Arjun Agarwal
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.